(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Active:	Yes
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT04996875
Trial Phases:	Phase II	Protocol IDs:	CGT9486-20-201 (primary) 2021-001010-10 NCI-2021-09477
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Cogent Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04996875

Summary

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of
patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive
SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.